Clinical Trials Epilepsy Events Programs 
Cannabis Law Report
DECEMBER 3, 2021
We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We
Cannabis Law Report
AUGUST 17, 2021
We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. percent, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial of 24.5 Chief Medical Officer of Marinus. “We Data Highlights.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MAY 19, 2021
Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.
Cannabis Law Report
DECEMBER 7, 2021
While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])
Cannabis Law Report
JANUARY 13, 2020
In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury. Commence clinical program in PTSD.
Cannabis Law Report
MARCH 2, 2020
This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). The dawn of a new era in psychedelic medicine. Potential IPOs within the next year.
Cannabis Law Report
JUNE 1, 2021
Drake received her bachelor’s degree from Wichita State University and is a graduate of the Harvard Business School Executive Leadership Program. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells.
Expert insights. Personalized for you.
52 
Let's personalize your content